Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison.
Ou SI, Prawitz T, Lin HM, Hong JL, Tan M, Proskorovsky I, Hernandez L, Jin S, Zhang P, Lin J, Patel J, Nguyen D, Neal JW. Ou SI, et al. Among authors: hong jl. Clin Lung Cancer. 2023 Dec 4:S1525-7304(23)00254-1. doi: 10.1016/j.cllc.2023.11.011. Online ahead of print. Clin Lung Cancer. 2023. PMID: 38114357
Response to "NGS, the New Global Standard?".
Ou SI, Hong JL, Christopoulos P, Lin HM, Vincent S, Churchill EN, Soeda J, Kazdal D, Thomas M, Stenzinger A. Ou SI, et al. Among authors: hong jl. J Thorac Oncol. 2023 Oct;18(10):e116-e118. doi: 10.1016/j.jtho.2023.07.022. J Thorac Oncol. 2023. PMID: 37758351 No abstract available.
Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutations.
Christopoulos P, Prawitz T, Hong JL, Lin HM, Hernandez L, Jin S, Tan M, Proskorovsky I, Lin J, Zhang P, Patel JD, Ou SI, Thomas M, Stenzinger A. Christopoulos P, et al. Among authors: hong jl. Lung Cancer. 2023 May;179:107191. doi: 10.1016/j.lungcan.2023.107191. Epub 2023 Apr 8. Lung Cancer. 2023. PMID: 37058788 Free article.
Distribution and Detectability of EGFR Exon 20 Insertion Variants in NSCLC.
Ou SI, Hong JL, Christopoulos P, Lin HM, Vincent S, Churchill EN, Soeda J, Kazdal D, Stenzinger A, Thomas M. Ou SI, et al. Among authors: hong jl. J Thorac Oncol. 2023 Jun;18(6):744-754. doi: 10.1016/j.jtho.2023.01.086. Epub 2023 Feb 3. J Thorac Oncol. 2023. PMID: 36738930 Free article.
BNT162b2 mRNA Vaccine-Induced Immune Response in Oral Fluids and Serum.
Seneviratne CJ, Balan P, de Alwis R, Udawatte NS, Herath T, Toh JZN, Tin GB, Ooi EE, Hong JLG, Ying JSX. Seneviratne CJ, et al. Among authors: hong jlg. Int Dent J. 2023 Jun;73(3):435-442. doi: 10.1016/j.identj.2022.09.005. Epub 2022 Nov 17. Int Dent J. 2023. PMID: 36402577 Free PMC article.
The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions.
Christopoulos P, Kluck K, Kirchner M, Lüders H, Roeper J, Falkenstern-Ge RF, Szewczyk M, Sticht F, Saalfeld FC, Wesseler C, Hackanson B, Dintner S, Faehling M, Kuon J, Janning M, Kauffmann-Guerrero D, Kazdal D, Kurz S, Eichhorn F, Bozorgmehr F, Shah R, Tufman A, Wermke M, Loges S, Brueckl WM, Schulz C, Misch D, Frost N, Kollmeier J, Reck M, Griesinger F, Grohé C, Hong JL, Lin HM, Budczies J, Stenzinger A, Thomas M. Christopoulos P, et al. Among authors: hong jl. Eur J Cancer. 2022 Jul;170:106-118. doi: 10.1016/j.ejca.2022.04.020. Epub 2022 May 20. Eur J Cancer. 2022. PMID: 35598358
84 results